STONY BROOK, N.Y., December 26, 2017 – Applied DNA Sciences, Inc. (NASDAQ: APDN), announced today it plans to release results for the fourth quarter and fiscal 2017 ended September 30, 2017 after market close on Thursday, December 28, 2017. In conjunction with the release, the Company has scheduled a conference call at 4:30 p.m. Eastern Time that will also be broadcast live over the internet.

What: Applied DNA’s Fourth Quarter and Fiscal 2017 Financial Results Conference Call
When: Thursday, December 28, 2017, at 4:30 p.m. Eastern Time
Where: Via phone by dialing +1 844-887-9402 or +1 412-317-6798 and ask for the Applied DNA call; via webcast.

A telephonic replay of the conference call will be available for one day and may be accessed by calling +1 877-344-7529 or +1 412-317-0088 with the passcode 10113295. The webcast will be archived in the Investor Relations section of the company’s website.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics and therapeutics.

We make life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. The proprietary DNA-based CertainT® platform can be used to identify, tag, test, and track products, to help assure authenticity, origin, traceability, sustainability and quality of products.

SigNature® DNA describes the core technology ingredient that is at the heart of a family of uncopyable, security and authentication solutions such as SigNature®T and fiberTyping®, targeted towards textiles and apparel, BackTrac® and DNAnet®, for anti-theft and loss prevention, and digitalDNA®, providing powerful track-and-trace. All provide a forensic chain of evidence, and can be used to prosecute perpetrators. Applied DNA Sciences is also engaged in the large-scale production of specific DNA sequences using the polymerase chain reaction.
Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Forward Looking Statements
The statements made by APDN in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 6, 2016, and our subsequent quarterly reports on Form 10-Q filed on February 9, 2017, May 11, 2017 and August 10, 2017, which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

Investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, shurry@lhai.com
Web: www.adnas.com | twitter: @APDN

STONY BROOK, N.Y. – December 20, 2017 – Applied DNA Sciences, Inc. (NASDAQ: APDN; “Applied DNA”) today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase an aggregate of 2,735,000 shares of common stock and warrants to purchase an aggregate of 2,735,000 shares of common stock in a registered direct offering with aggregate gross proceeds of $4,786,250, exclusive of warrant exercise proceeds.  Each share of common stock is being sold together with a warrant to purchase one share of common stock at a combined effective price to the public of $1.75.  The warrants will be immediately exercisable at a price of $2.00 per share of common stock and will expire five years from the date of issuance. The shares of common stock and the accompanying warrants can only be purchased together in the offering but will be issued separately.  The offering is expected to close on or about December 22, 2017, subject to the satisfaction of customary closing conditions.

Maxim Group LLC acted as the exclusive placement agent for the offering.

After deducting the placement agent’s commission and other estimated offering expenses payable by Applied DNA, the net proceeds to Applied DNA are anticipated to be approximately $4.2 million, not including any amounts Applied DNA will receive upon the exercise of the warrants. Applied DNA intends to use the net proceeds of the offering for working capital, capital expenditures, business development and research and development expenditures, and acquisitions of new technologies or businesses.

The securities described above are being offered under the Company’s shelf registration statement on Form S-3 (No. 333-218158), including a base prospectus, previously filed with and declared effective by the U.S. Securities and Exchange Commission (SEC). The securities will be offered by means of a prospectus supplement and accompanying prospectus, forming a part of the effective registration statement. The prospectus supplement and accompanying prospectus related to the offering will be filed with the SEC and will be available on the website of the SEC at http://www.sec.gov. Electronic copies of the prospectus supplement and accompanying prospectus also may be obtained from Maxim Group LLC, 405 Lexington Avenue, 2nd Floor, New York, NY 10174, at 212-895-3745. Before you invest, you should read the prospectus supplement and the accompanying prospectus in the  registration statement and other documents Applied DNA has filed or will file with the SEC for more complete information about Applied DNA and the offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Applied DNA Sciences, Inc.
Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. The proprietary DNA-based CertainTT® Platform can be used to identify, tag, track, and trace products, to help assure authenticity, origin, traceability and quality of products. SigNature® DNA describes the core technology ingredient that is at the heart of a family of uncopyable, security and authentication solutions such as SigNature® T and fiberTyping®, targeted toward textiles and apparel, BackTrac® and DNAnet®, for anti-theft and loss prevention, and digitalDNA®, providing powerful track- and-trace. All provide a forensic chain of evidence, and can be used to prosecute perpetrators. Applied DNA is also engaged in the large-scale production of specific DNA sequences using the polymerase chain reaction.

Forward-Looking Statements
The statements made by APDN in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our history of losses, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 6, 2016,  our subsequent quarterly reports on Form 10-Q filed on February 9, 2017, May 11, 2017 and August 10, 2017 and our Registration Statement on Form S-3 (SEC File No. 333-218158) and Prospectus Supplement to be filed which are or will be available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

Contacts
Investor contact: Sanjay M. Hurry, 212-838-3777, LHA, shurry@lhai.com
Media contact: Cheryl Schneider, Dian Griesel Int’l, 212-825-3210, cschneider@dgicomm.com
Web: www.adnas.com, Twitter: @APDN

STONY BROOK, N.Y. December 18, 2017 – Applied DNA Sciences, Inc. (NASDAQ: APDN; “Applied DNA”, “the Company”), and Colorcon, Inc. (Colorcon) have entered into a technology license memorandum of understanding (“MOU”) that combines Applied DNA’s proprietary molecular taggant and authentication technology with Colorcon’s portfolio of film coating systems, inks and color dispersions for use in solid oral dosage forms in the pharmaceutical and nutraceutical industries.  This collaboration will commercialize a platform for traceability directly on dose, and is intended to significantly reduce the risks associated with counterfeit and falsified medications entering the drug supply chain. The MOU is non-binding and is expected to be followed by a definitive agreement.

Colorcon has an international reputation as a pharmaceutical supplier of choice based on superior product quality and technical support, extensive regulatory assistance and reliable supply from eleven manufacturing facilities worldwide.  Founded on a commitment to technology, research and development, Colorcon is always looking for opportunities to address industry challenges with leading edge products and services for the pharmaceutical market.  Serialization of packaging begins to mitigate the risks associated with counterfeit drugs, but adoption of multiple technologies will further secure supply chain integrity. 

“By incorporating molecular taggants from Applied DNA into our specialty excipients, Colorcon is able to offer a simple and seamless solution to our pharmaceutical and nutraceutical customers to address counterfeiting and product diversion issues”, says Kelly Boyer, Film Coating GM at Colorcon.

“This MOU is the culmination of a multi-year effort to extend the applicability of our molecular taggant technology to an industry whose participants are moving quickly to address supply chain concerns and comply with federal serialization mandates across multiple continents, ” said Dr. James Hayward, president and CEO of Applied DNA. “In partnering with Colorcon, we are aligned with a truly innovative, high quality science and technology company in bringing our novel technology to the center of the pharmaceutical industry. The MOU complements our Tag, Test and Track transparency with a strong global sales and marketing team. The result will be end-to-end protection of a significant portion of the total addressable pharmaceutic market (TAM). This will be especially important in the US, which alone holds 45% of the global pharmaceuticals market.

“This MOU presents what we believe is a breakthrough opportunity to help pharmaceutical companies enhance patient safety and reduce risk by using intelligent data and analytics gathered from authentication of the dosage form themselves. By better understanding trade flows and vulnerabilities in a complex global supply chain, we are helping pharmaceutical leaders make better decisions on managing distribution patterns, frequent monitoring and deploying preventative measures for their products around the world,” said Bob Miglani, Chief of Business Development at Applied DNA.

About Colorcon®
Colorcon is a world leader in the development, supply and technical support of formulated film coating systems, modified release technologies, and functional excipients for the pharmaceutical industry. Our best-in-class products and technologies are complemented by our extensive application data and value-added services to support all phases of solid oral dose design and development. Our focus on market issues and technology development has earned Colorcon an international reputation as a pharmaceutical supplier of choice.  That reputation is based on the superior product quality, unparalleled technical support, extensive regulatory assistance and reliable supply from multiple locations Colorcon has 11 manufacturing facilities including seven film coating plants, 21 technical service laboratories globally and more than 1200 employees exclusively dedicated to its customer base.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics and therapeutics.

We make life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. The proprietary DNA-based “CertainT®” platform can be used to identify, tag, test, and track products, to help assure authenticity, origin, traceability, sustainability and quality of products.

SigNature^® DNA describes the core technology ingredient that is at the heart of a family of uncopiable, security and authentication solutions such as SigNature^® T and fiberTyping^®, targeted toward textiles and apparel, BackTrac® and DNAnet^®, for anti-theft and loss prevention, and digitalDNA^®, providing powerful track-and-trace. All provide a forensic chain of evidence, and can be used to prosecute perpetrators. Applied DNA Sciences is also engaged in the large-scale production of specific DNA sequences using the polymerase chain reaction.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

The Company’s common stock is listed on NASDAQ under the symbol APDN, and its warrants are listed under the symbol APDNW.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our history of losses, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 6, 2016, and our subsequent quarterly reports on Form 10-Q filed on February 9, 2017, May 11, 2017, and August 10, 2017 which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

Investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, shurry@lhai.com
media contact: Cheryl Schneider, DGI Comm, 212-825-3210, cschneider@dgicomm.com
program contact: Bob Miglani, Chief of Business Development, Applied DNA Sciences, (631) 240-8800 bob.miglani@adnas.com
web: www.adnas.com, twitter: @APDN

STONY BROOK, N.Y. (December 15, 2017) – Applied DNA Sciences, Inc. (NASDAQ: APDN; “Applied DNA”) today announced selected preliminary unaudited financial results for the full fiscal year and quarter ended September 30, 2017.

Preliminary (Unaudited) Fiscal 2017 Financial Results:

• Revenues increased 13% to $4.8 million as compared to $4.2 million in the prior fiscal year. The increase in year-over-year total revenues is attributable to increases in product revenue of approximately $1.4 million in the textile industry primarily for protecting cotton supply chains, offset by a net decrease in service revenues from government contract awards of approximately $800 thousand, primarily as a result of two awards which expired in July and August 2016.
• Total operating expenses were $16.5 million, compared with $15.2 million in the prior fiscal year, an increase of approximately $1.3 million or 8%. The increase is primarily attributable to an increase in stock based compensation expense, offset by a decrease in R&D due to the expiration of the two government contract awards.
• Net loss for fiscal 2017 was $12.9 million, or $0.49 per share, compared with a net loss of $12.2 million, or $ 0.51 per share, in the prior fiscal year.

Preliminary (Unaudited) Fiscal Fourth Quarter Results:

• Revenues decreased 30% for the fourth quarter of fiscal 2017 to $1.1 million, compared with $1.6 million reported in the fourth quarter of fiscal 2016, and decreased 36% from the $1.8 million reported in the third fiscal quarter ended June 30, 2017. The year-over-year quarterly decrease in revenues resulted primarily from decreased sales to the textile industry. The year-over-year quarterly decrease in textile industry sales was due to the fact that the shipments of DNA concentrate took place in the third quarter of fiscal 2017 as compared to fiscal 2016 when they took place in the fourth quarter, as well as the restructuring of payment terms under the June 23, 2017 licensing agreement with Himatsingka America, Inc. The timing of the shipments is also the reason for the decrease in revenues for the fourth quarter of fiscal 2017 as compared to the prior fiscal quarter.
• Total operating expenses remained fairly flat at $3.7 million for the fourth fiscal quarter of 2017, compared with $3.6 million in the prior fiscal year’s quarter.
• Net loss for the quarter ended September 30, 2017 was $2.9 million, or $0.10 per share, compared with a net loss of $2.4 million, or $0.10 per share, for the quarter ended September 30, 2016 and a net loss of $2.6 million, or $0.10 per share, for the quarter ended June 30, 2017.

The Company also announced that it anticipates filing its Annual Report on Form 10-K for the fiscal year ended September 30, 2017 with the Securities and Exchange Commission by December 29, 2017.

“Our fiscal 2017 performance reflects growing market awareness and adoption of our DNA technology platform in our key business verticals, resulting in the largest pipeline of pilot projects and highest annual recurring revenue run-rate in Applied DNA’s history,” stated Dr. James Hayward, president and CEO. “In addition to seeing increasing long-term demand in our textile business, we have broadened the applicability of our technology platform in markets adjacent to our core markets and are successfully demonstrating to manufacturers that molecular tag technology can be strategic to their business goals. This is yielding partnerships with market leaders such as Videojet in inkjet printing and marking systems and Rosier in fertilizer that accelerates our time-to-revenue in their respective verticals. We believe that our successes in fiscal 2017 place us firmly on a path to revenue growth in fiscal 2018.”

Preliminary Results
The financial data contained in this press release are unaudited, preliminary, based upon Applied DNA’s good faith estimates and subject to completion of Applied DNA’s financial closing procedures. While Applied DNA expects that its final financial results for the fiscal year and quarter ended September 30, 2017, following the completion of its financial closing procedures, will generally be consistent with the amounts provided in this press release, Applied DNA’s actual results may differ materially from these estimates as a result of the completion of its financial closing procedures, as well as final adjustments and other developments that may arise between now and the time that its financial results for the fiscal year and quarter ended September 30, 2017 are finalized.

The results provided in this press release are preliminary and subject to completion and audit of Applied DNA’s financial statements in conjunction with the Company’s 2017 Form 10-K filing with the Securities and Exchange Commission anticipated to occur by December 29, 2017.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics and therapeutics.

We make life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. The proprietary DNA-based “CertainT®” platform can be used to identify, tag, test, and track products, to help assure authenticity, origin, traceability, sustainability and quality of products.

SigNature® DNA describes the core technology ingredient that is at the heart of a family of uncopiable, security and authentication solutions such as SigNature® T and fiberTyping®, targeted toward textiles and apparel, BackTrac™ and DNAnet®, for anti-theft and loss prevention, and digitalDNA®, providing powerful track-and-trace. All provide a forensic chain of evidence, and can be used to prosecute perpetrators. Applied DNA Sciences is also engaged in the large-scale production of specific DNA sequences using the polymerase chain reaction.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

The Company’s common stock is listed on NASDAQ under the symbol APDN, and its warrants are listed under the symbol APDNW.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 6, 2016, and our subsequent quarterly reports on Form 10-Q filed on February 9, 2017, May 11, 2017, and August 10, 2017 which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

Investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777
media contact: Cheryl Schneider, DGI Comm, 212-825-3210, cschneider@dgicomm.com
web: www.adnas.com
twitter: @APDN 

DNA tagging program continues with aim of preventing vehicle theft

STONY BROOK, N.Y. (December 14, 2017) – Applied DNA Sciences, Inc. (NASDAQ: APDN; “Applied DNA”, “the Company”), today announced the renewal of their contract to provide SigNature^® DNA via Safesolution SmartDNA AB, its Swedish Distributor, to a prestige German car manufacturer to prevent vehicle theft.

This announcement builds on the success of our previous contract, which proved highly effective in preventing vehicle theft of marked vehicles, and aiding in the recovery and identification of stolen parts. The continuation of the program will ensure new vehicles imported into Sweden will be protected.

As part of the program, high value components for all of the manufacturer’s new cars are tagged with SigNature DNA (known as Smart DNA^® in Sweden) as they enter the country. Each vehicle is tagged with a unique molecular code, enabling police to trace stolen vehicles and components back to the original owner. The program aims to keep insurance costs low for car owners and to protect cars from criminals.

Tagging vehicles with SmartDNA has proved to be a powerful tool for police. In the previous two years, DNA tagging has helped police in a number of countries to gather forensic evidence and intelligence on criminal networks.

“We are also working to deliver further value with our data analytical capability to assist stakeholders in the reduction of vehicle crime including vehicle owners, manufacturers, insurers and law enforcement.  This will add to the already powerful deterrence value of SmartDNA,” said Tony Benson, Managing Director of Applied DNA Sciences Europe.

Safesolution SmartDNA AB has been Applied DNA’s Swedish distributor for the last 7 years. “The Prestige German Car Manufacturer is a very demanding client who requires the very highest service offerings for their customers.  It is a great pleasure to work with them and we are delighted to have been given the opportunity to continue to build our relationship. We plan to continually improve and enhance our service offerings to exceed their expectations,” commented Leif Svensson, Founder and Chairman of Safesolution SmartDNA AB.

SigNature DNA has been used in Europe since 2008 to deter crime and convict criminals. To date, SigNature DNA evidence has been used in conviction of over 115 criminals, leading to more than 540 years of prison time. Many more cases are still pending.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics and therapeutics.

We make life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. The proprietary DNA-based “CertainT®” platform can be used to identify, tag, test, and track products, to help assure authenticity, origin, traceability, sustainability and quality of products.

SigNature® DNA describes the core technology ingredient that is at the heart of a family of uncopyable, security and authentication solutions such as SigNature®T and fiberTyping®, targeted towards textiles and apparel, BackTrac™ and DNAnet®, for anti-theft and loss prevention, and digitalDNA®, providing powerful track-and-trace. All provide a forensic chain of evidence, and can be used to prosecute perpetrators. Applied DNA Sciences is also engaged in the large-scale production of specific DNA sequences using the polymerase chain reaction.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Forward-Looking Statements
The statements made by APDN in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 6, 2016, and our subsequent quarterly reports on Form 10-Q filed on February 9, 2017, May 11, 2017 and August 10, 2017  which are available at www.sec.gov. APDN , undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

Contacts
investor contact: Sanjay Hurry, 212-838-3777, shurry@lhai.com
Media: Cheryl Schneider, Dian Griesel Int’l, 212-825-3210, cschneider@dgicomm.com
Program Contact: Tony Benson, Managing Director, Applied DNA Europe, +1 44 (0) 7552 429341 tony.benson@adnas.com
web: www.adnas.com, twitter: @APDN

Company to Introduce DNA-Tagged Fertilizers to Additional Markets. Demand Driven by Supply Chain Needs for Product Purity and Security, First Country to Mandate DNA Tagging of All Domestic Fertilizers.

STONY BROOK, N.Y. (December 5, 2017) – Applied DNA Sciences, Inc. (NASDAQ: APDN; “Applied DNA”, “the Company”), today announced that it will introduce DNA-tagged fertilizer to Turkey and countries in West Africa and Asia following strong interest in the use of the Company’s molecular tagging technology to prevent fertilizer adulteration, secure supply chains to the global farming industry and track the origin of fertilizers used for nefarious purpose. Early planning workshops indicate new tagged fertilizer may enter targeted markets during early calendar 2018 and additional locations thereafter throughout calendar 2018.

Applied DNA previously completed a pilot project for the large-scale molecular tagging of fertilizer that was successfully tracked through a West African supply chain. Following this success, the Company began to to determine how best to introduce DNA-tagged fertilizer and associated authentication systems, into new markets. According to a 2015 study by the Food and Agriculture Organization of the United Nations, Asia is the largest consumer of fertilizer in the world, accounting for 60% of total fertilizer consumption.

In the Republic of Turkey, legislators have mandated DNA-tagging of all domestically produced fertilizer by January 1, 2018, and secure packaging, including the use of secured bar codes which could possibly be enabled by the platform recently commercialized through the Videojet and Applied DNA collaboration. This mandate comes in response to a series of acts of terror that utilized fertilizer-based explosives in Turkey in 2016. Applied DNA has been in communication with Turkish fertilizer manufacturers since early 2016 and to the Company’s knowledge, is the only company to have publically demonstrated the capacity to tag fertilizer at scale and successfully track it through all aspects of the supply chain. As of this date, the Company has no specific orders from Turkey. Applied DNA is also developing a method it believes will allow detection of fertilizer tags, even after an explosion. This would allow governments and law enforcement to track the origins of fertilizers used in improvised explosive devices.

“The introduction of our technology platform to these additional geographies that cumulatively represent the majority of world demand for fertilizer is a clear demonstration of our ability to service large commercial ecosystems,” said Dr. James Hayward, president and CEO of Applied DNA. “From textiles to the biopharma industry and now fertilizer, our technology platform is increasingly being viewed by supply chain participants as strategic to their business goals.”

Tony Benson, managing director of Applied DNA in Europe, stated, “Tracking fertilizers in a large, complex commercial ecosystem is an unmet demand required by farmers and governments, especially those dependent upon their agro economies.  Our solution is practical, and readily implemented.”

Continued Mr. Benson, “The impact of our technology and the significant benefits to at-risk families in countries where many people are already disadvantaged cannot be over-estimated.  People are starving and economies are suffering due to the blatant cheating that is taking place of which there are many published examples of fertilizers being adulterated leading to crop failures.  We are delighted and humbled to be part of a technical solution that will positively change the wellbeing of so many people.”

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics and therapeutics.

We make life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. The proprietary DNA-based “CertainT®” platform can be used to identify, tag, test, and track products, to help assure authenticity, origin, traceability, sustainability and quality of products.

SigNature® DNA describes the core technology ingredient that is at the heart of a family of uncopyable, security and authentication solutions such as SigNature®T and fiberTyping®, targeted towards textiles and apparel, BackTrac™ and DNAnet®, for anti-theft and loss prevention, and digitalDNA®, providing powerful track-and-trace. All provide a forensic chain of evidence, and can be used to prosecute perpetrators. Applied DNA Sciences is also engaged in the large-scale production of specific DNA sequences using the polymerase chain reaction.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Forward-Looking Statements
The statements made by APDN in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 6, 2016, and our subsequent quarterly reports on Form 10-Q filed on February 9, 2017, May 11, 2017 and August 10, 2017  which are available at www.sec.gov. APDN , undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

Contacts
investor contact: Sanjay Hurry, 212-838-3777, shurry@lhai.com
Media: Cheryl Schneider, Dian Griesel Int’l, 212-825-3210, cschneider@dgicomm.com
Program Contact: Brian Viscount, Executive Director Product Management, 631-240-8800, brian.viscount@adnas.com
web: www.adnas.com, twitter: @APDN

STONY BROOK, N.Y. (December 5, 2017) – Applied DNA Sciences, Inc. (NASDAQ: APDN; “Applied DNA”, “the Company”), announced today that Dr. James Hayward, president & CEO, will present at Imperial Capital’s 2017 Security Investor Conference at the Intercontinental New York Barclay on Thursday, December 7 at 9:00 a.m. ET.  Dr. Hayward will present to an audience of investors and industry professionals and will be available for one-on-one meetings with institutional investors. Dr. Hayward’s presentation at the conference will be webcast through the Investor Relations section of the company’s website.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics and therapeutics.

We make life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. The proprietary DNA-based “CertainT®” platform can be used to identify, tag, test, and track products, to help assure authenticity, origin, traceability, sustainability and quality of products.

SigNature® DNA describes the core technology ingredient that is at the heart of a family of uncopyable, security and authentication solutions such as SigNature®T and fiberTyping®, targeted towards textiles and apparel, BackTrac™ and DNAnet®, for anti-theft and loss prevention, and digitalDNA®, providing powerful track-and-trace. All provide a forensic chain of evidence, and can be used to prosecute perpetrators. Applied DNA Sciences is also engaged in the large-scale production of specific DNA sequences using the polymerase chain reaction.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Forward-Looking Statements
The statements made by APDN in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 6, 2016, and our subsequent quarterly reports on Form 10-Q filed on February 9, 2017, May 11, 2017 and August 10, 2017  which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

Contacts
investor contact: Sanjay Hurry, 212-838-3777, shurry@lhai.com
web: www.adnas.com, twitter: @APDN

Unique PCR-based bulk DNA manufacturing offers purity, simplicity and speed to developers of DNA-based therapeutics; company seeing growing interest from market participants as awareness of proprietary processes increases

STONY BROOK, N.Y. November 30, 2017. Applied DNA Sciences, Inc. (NASDAQ: APDN, “Applied DNA”, “the Company”), has begun initial Research and Development pilots for the manufacture of DNA for use in DNA-based therapeutics for two companies. Several other companies have requested proposals for additional DNA-based therapeutics. In one project, the Company is engaged in evaluation of a DNA therapeutic with a US-based customer and in the second, the Company is conducting an evaluation of two animal vaccines with Evvivax srl, an Italian biotech company focused on healthcare for companion animals. These pilots will be developed using the Company’s proprietary and patented large-scale PCR (polymerase chain reaction) DNA production processes and devices.

“We are seeing strong business momentum in our biopharm vertical as awareness of and interest in our proprietary processes and devices for the production of DNA using PCR methods increases, thereby offering us an additional driver of long-term and profitable growth. As our team’s sophistication, breadth of experience and recognition by leading scientists continues to mature, we are fielding pilot requests that are greater in number, financial significance and duration. Recently, we have fielded six new requests for pilot quotation for DNA therapeutics,” commented Dr. James Hayward, president and CEO of Applied DNA.

Dr. Luigi Aurisicchio, Chief Executive and Scientific Officer of Evvivax srl, stated: “We are pleased with the technical capabilities and customer service of the Applied DNA team. PCR-production of DNA offers advantages over ‘plasmid produced’ DNA. The goal of this pilot is to quantify those advantages for use in our animal vaccines.” USDA has already approved a number of DNA-vaccines for animals.

The new pilots complement current agreements to supply PCR-produced DNA to suppliers of diagnostics. The Company’s current customers develop the diagnostic tests, while Applied DNA acts as the long-term supplier of their customized DNA. The Company continues to cultivate opportunities in diagnostics for its PCR-produced DNA that is cleaner, faster, and more easily modified than DNA made from legacy technologies.

This is a natural extension to the Company’s roadmap of DNA-tagging commercial pharmaceutics to secure supply chains of approved drugs. The DNA tags are short, have no biological function by design, and are present as traceable “excipients,” which aid in the manufacture of finished drugs, but are not the Active Pharmaceutic Ingredients (APIs). Now the Company’s portfolio will include (longer) functional DNA therapeutics.

“We have the know-how in place to drive the Company’s new role in the DNA diagnostics and therapeutics market, and the commercial connectivity between the two. Our competencies in PCR enable us to transition from bench to production quickly. Our existing industrial taggant and new biomedical programs complement one another perfectly, steadily improving our capacity to manufacture simple (short) and complex (long) DNA sequences. Our cutting-edge methods to design and detect DNA support all of these markets,” remarked Dr. Mike Hogan, Vice President of Life Sciences for Applied DNA.

DNA vaccines have until now, been based primarily upon “plasmid” delivery. Plasmids are small, circular, double-stranded molecules of DNA found in bacteria and yeast. These molecules have traditionally been the tools used to manufacture DNA. However, a plasmid-based technology for gene therapy suffers from a number of drawbacks that include: a) the active DNA only represents about 30-50% of the plasmid, b) the remaining 50-70% of the plasmid contains multiple genetic components unrelated to the DNA vaccine that may have unintended consequences in humans, c) the plasmid-containing bacteria must be grown in very large vessels, over many days, to yield DNA supplies adequate for vaccines, d) the bacteria used to produce the plasmids contain toxins and pyrogens, that can cause illness and fevers if present in the DNA preparation that is given to a patient.

Dr. Stephen Hughes, Director of DNA Programs, stated: “Our network of contacts includes thought-leaders in industrial biotech, personalized medicine, and the requirements for precision diagnosis, and DNA therapeutics. It is very rewarding to be able to deploy the newest development in our sciences, for benefit in industry and medicine.”

PCR-produced DNA is very pure, especially compared to plasmids. Bacteria are not used during manufacturing. The reaction starting materials are limited to the nucleotides (adenine, thymine, guanine and cytosine) contained within the target sequence, an enzyme called polymerase, the template for the target DNA and primers. Almost all the starting materials are consumed during the reaction. Any residual reactants are easily removed during purification of the target DNA, due especially to the latter’s far greater size. Most importantly, the PCR-produced DNA contains only the DNA elements required for DNA therapeutic function and is free of any of the extraneous genetic elements intrinsic to a plasmid-based carrier.

About Evvivax
EVVIVAX is a Biotech company based in Rome, Italy. EVVIVAX aims at translating scientific breakthrough achievements in Cancer Immunotherapy into marketed innovative products in Veterinary and subsequently in Human Oncology. Veterinary Oncology is an extraordinary growing market opportunity: one in every four dogs will develop cancer during its lifetime and this generally kills nearly half of pet dogs over the age ten. EVVIVAX Cancer Vaccines are based on an Adenoviral vector/DNA platform technology. EVVIVAX’ frontline candidates are two therapeutic cancer vaccines for canine tumors: Tel-eVax, targeting Telomerase (TERT), a key molecule in Oncology. b) Erb-eVax, against HER2/neu oncogene, a well-known and validated target. The main cancer types suitable for these immunotherapies are: Lymphomas, Breast, Osteosarcoma and Transitional cell carcinomas.

EVVIVAX stems from new, European platform technologies, and aims to offer novel therapeutic avenues to pet cancer patients, with the strong translational potential to complement current human Immune-Oncology approaches in the next future.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics and therapeutics.

We make life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. The proprietary DNA-based “CertainT^®” platform can be used to identify, tag, test, and track products, to help assure authenticity, origin, traceability, sustainability and quality of products.

SigNature^® DNA describes the core technology ingredient that is at the heart of a family of uncopyable, security and authentication solutions such as SigNature^® T and fiberTyping^®, targeted toward textiles and apparel, BackTrac™ and DNAnet^®, for anti-theft and loss prevention, and digitalDNA^®, providing powerful track-and-trace. All provide a forensic chain of evidence, and can be used to prosecute perpetrators. Applied DNA Sciences is also engaged in the large-scale production of specific DNA sequences using the polymerase chain reaction.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

The Company’s common stock is listed on NASDAQ under the symbol APDN, and its warrants are listed under the symbol APDNW.

Forward Looking Statements
The statements made by APDN in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 6, 2016, and our subsequent quarterly reports on Form 10-Q filed on February 9, 2017, May 11, 2017 and August 10, 2017, which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

CONTACTS
Investors:
LHA Investor Relations
Sanjay M. Hurry, 212-838-3777
shurry@lhai.com

Media:
Dian Griesel Int’l
Cheryl Schneider, 212-825-3210
cschneider@dgicomm.com

Program:
Brian Viscount, 631-240-8800
Executive Director Product Management
brian.viscount@adnas.com

web: www.adnas.com
twitter: @APDN

Co-Branded Applied DNA SigNature® Molecular-Tagged Videojet Inks and Co-Branded Printer on Display at Booth #1019

STONY BROOK, NY (November 28, 2017) – Applied DNA Sciences, Inc. (“Applied DNA,” “the company,” NASDAQ: APDN) will exhibit its new security print platform developed with Videojet Technologies (Videojet) at the Defense Manufacturing Conference 2017 (DMC 2017) in Tampa, FL on December 4-6 at Booth #1019. Janice Meraglia, Vice President of Government & Military Programs, and Bob MacDowell, Director of Government & Military Programs, will be attending the conference.

The platform utilizes Videojet’s recently released 1860 continuous inkjet printer, which is co-branded with Applied DNA, along with co-branded Videojet inks that incorporate Applied DNA’s unique SigNature® molecular tag into each individual Smart Cartridge™ ink cartridge. The SigNature molecular ink is a turnkey, high-volume ink that offers per-part traceability. The inks are brand-specific, enabling each brand to tag, test and track their products from source to shelf under a CertainT® licensing agreement.

The initial rollout of co-branded SigNature molecular-tagged inks includes an aerospace-approved ink. This durable black ink was chosen to qualify first, due to its specific application and use in the U.S. military and aerospace industry for item unique identifier (IUID) tags for an array of critical components spanning several Federal Supply Groups (FSGs).

Janice Meraglia said, “We look forward to showcasing this unique platform, which is designed to enable defense suppliers to forensically tag products and packaging. Once tagged, other supply chain participants can independently conduct in-field tests along the supply chain, track globally to certify product claims, and prevent diversion and counterfeits.”  The DMC is where top government and industry leaders and manufacturing subject matter experts gather to communicate and collaborate on policies, strategic direction, best practices, funding opportunities, and the latest innovations in support of defense manufacturing priorities. The DMC will be conducted simultaneously with the Diminishing Manufacturing Sources and Material Shortages (DMSMS) Conference.

If you are interested in meeting with Applied DNA at the conference, please contact Janice Meraglia directly at Janice.meraglia@adnas.com.

About Videojet Technologies
Videojet Technologies is a world-leader in the product identification market, providing in-line printing, coding, and marking products, application specific fluids, and product life cycle services. Our goal is to partner with our customers in the consumer packaged goods, pharmaceutical, and industrial goods industries to improve their productivity, to help protect and grow their brands, and to stay ahead of industry trends and regulations. With our customer application experts and technology leadership in continuous inkjet (CIJ), thermal inkjet (TIJ), laser marking, thermal transfer overprinting (TTO), case coding and labeling, and wide array printing, Videojet has more than 345,000 printers installed worldwide. Our customers rely on Videojet products to print on over ten billion products daily. Customer sales, application, service, and training support is provided by direct operations with over 4,000 team members in 26 countries worldwide. In addition, the Videojet distribution network includes more than 400 distributors and OEMs, serving 135 countries.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics and therapeutics.

We make life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. The proprietary DNA-based “CertainT®” platform can be used to identify, tag, test, and track products, to help assure authenticity, origin, traceability, sustainability and quality of products.

SigNature® DNA describes the core technology ingredient that is at the heart of a family of uncopyable, security and authentication solutions such as SigNature®T and fiberTyping®, targeted towards textiles and apparel, BackTrac™ and DNAnet®, for anti-theft and loss prevention, and digitalDNA®, providing powerful track-and-trace. All provide a forensic chain of evidence, and can be used to prosecute perpetrators. Applied DNA Sciences is also engaged in the large-scale production of specific DNA sequences using the polymerase chain reaction.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Forward-Looking Statements
The statements made by APDN in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 6, 2016, and our subsequent quarterly reports on Form 10-Q filed on February 9, 2017, May 11, 2017 and August 10, 2017  which are available at www.sec.gov. APDN , undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

Contacts
investor contact: Sanjay Hurry, 212-838-3777, shurry@lhai.com
Media: Cheryl Schneider, Dian Griesel Int’l, 212-825-3210, cschneider@dgicomm.com
Program Contact: Janice Meraglia, 631-240-8821, janice.meraglia@adnas.com
web: www.adnas.com, twitter: @APDN